DTG/3TC

DRUG5 trials

Sponsors

ViiV Healthcare, University of Nairobi, Affiliated Hospital of Nantong University, Instituto Mexicano del Seguro Social

Conditions

Antiretroviral TreatmentHIVHIV InfectionHIV InfectionsHIV-1-infectionMetabolic Syndrome

Phase 3

A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF

Active, not recruitingNCT05911360

ViiV HealthcareHIV, HIV Infections

Start: 2023-01-31End: 2026-01-13Updated: 2025-12-01

A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy

Active, not recruitingNCT05917509

ViiV HealthcareHIV Infections

Start: 2023-07-06End: 2026-04-22Updated: 2026-03-09

B/F/TAF to DTG/3TC Switch Study

Active, not recruitingNCT06444620

University of NairobiHIV-1-infection

Start: 2024-07-22End: 2026-12-22Target: 240Updated: 2025-09-05

Phase 4

Safety, Tolerability and Effectiveness of DTG/3TC vs BIC/TAF/FTC in PWH Without Antiretroviral Experience

RecruitingNCT07031063

Instituto Mexicano del Seguro SocialAntiretroviral Treatment, HIV Infection, Metabolic Syndrome

Start: 2025-04-01End: 2028-12-01Target: 124Updated: 2025-06-26

Unknown Phase

Good-first: B/F/TAF As First-line ART

RecruitingNCT06619288

Affiliated Hospital of Nantong UniversityHIV Infection

Start: 2024-07-01End: 2026-06-30Target: 630Updated: 2024-10-01